[HTML][HTML] Apatinib plus gefitinib as first-line treatment in advanced EGFR-mutant NSCLC: the phase III ACTIVE study (CTONG1706)
H Zhao, W Yao, X Min, K Gu, G Yu, Z Zhang… - Journal of thoracic …, 2021 - Elsevier
Introduction Blocking vascular endothelial growth factor pathway can enhance the efficacy of
EGFR tyrosine kinase inhibitors in EGFR-mutant NSCLC. ACTIVE is the first phase 3 study …
EGFR tyrosine kinase inhibitors in EGFR-mutant NSCLC. ACTIVE is the first phase 3 study …
[HTML][HTML] Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance
F Li, T Zhu, B Cao, J Wang, L Liang - European Journal of Cancer, 2017 - Elsevier
Background Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs)-
rechallenged therapy for EGFR-mutant non-small cell lung cancer (NSCLC) patients who …
rechallenged therapy for EGFR-mutant non-small cell lung cancer (NSCLC) patients who …
[HTML][HTML] Pembrolizumab in combination with erlotinib or gefitinib as first-line therapy for advanced NSCLC with sensitizing EGFR mutation
JCH Yang, SM Gadgeel, LVD Sequist, CL Wu… - Journal of Thoracic …, 2019 - Elsevier
Introduction Anti-EGFR agents are standard treatments for patients with EGFR-mutant
advanced NSCLC. The feasibility of combining erlotinib or gefitinib with the anti …
advanced NSCLC. The feasibility of combining erlotinib or gefitinib with the anti …
Randomized Trial of Afatinib Plus Cetuximab Versus Afatinib Alone for First-Line Treatment of EGFR-Mutant Non–Small-Cell Lung Cancer: Final Results From SWOG …
SB Goldberg, MW Redman, R Lilenbaum… - Journal of Clinical …, 2020 - ascopubs.org
PURPOSE The irreversible ErbB family tyrosine kinase inhibitor (TKI) afatinib plus the EGFR
monoclonal antibody cetuximab was previously shown to overcome resistance to EGFR …
monoclonal antibody cetuximab was previously shown to overcome resistance to EGFR …
[HTML][HTML] Afatinib and cetuximab in four patients with EGFR Exon 20 insertion–positive advanced NSCLC
B van Veggel, AJ de Langen, SMS Hashemi… - Journal of Thoracic …, 2018 - Elsevier
Introduction EGFR exon 20 insertions comprise 4% to 9% of EGFR mutated NSCLC. Despite
being an oncogenic driver, they are associated with primary resistance to EGFR tyrosine …
being an oncogenic driver, they are associated with primary resistance to EGFR tyrosine …
[HTML][HTML] Randomized phase 2 study of osimertinib plus bevacizumab versus osimertinib for untreated patients with nonsquamous NSCLC harboring EGFR mutations …
H Kenmotsu, K Wakuda, K Mori, T Kato… - Journal of thoracic …, 2022 - Elsevier
Introduction To evaluate the efficacy and safety of osimertinib plus bevacizumab for
previously untreated patients with advanced nonsquamous NSCLC harboring EGFR …
previously untreated patients with advanced nonsquamous NSCLC harboring EGFR …
Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor …
S Lu, L Wu, H Jian, Y Cheng, Q Wang… - The Lancet …, 2023 - thelancet.com
Background In the first interim analysis of the ORIENT-31 trial, compared with chemotherapy
alone, sintilimab plus bevacizumab biosimilar IBI305 plus chemotherapy (pemetrexed and …
alone, sintilimab plus bevacizumab biosimilar IBI305 plus chemotherapy (pemetrexed and …
[HTML][HTML] Osimertinib plus durvalumab versus osimertinib monotherapy in EGFR T790M–positive NSCLC following previous EGFR TKI therapy: CAURAL brief report
JCH Yang, FA Shepherd, DW Kim, GW Lee… - Journal of Thoracic …, 2019 - Elsevier
Introduction Osimertinib is a third-generation EGFR-tyrosine kinase inhibitor (TKI).
Durvalumab is an anti–programmed death ligand 1 monoclonal antibody. The phase III …
Durvalumab is an anti–programmed death ligand 1 monoclonal antibody. The phase III …
[HTML][HTML] Safety, efficacy, and pharmacokinetics of almonertinib (HS-10296) in pretreated patients with EGFR-mutated advanced NSCLC: a multicenter, open-label …
JCH Yang, DR Camidge, CT Yang, J Zhou… - Journal of Thoracic …, 2020 - Elsevier
Abstract Introduction Almonertinib (HS-10296) is a novel, third-generation EGFR tyrosine
kinase inhibitor (EGFR TKI) that targets both EGFR-sensitizing and T790M resistance …
kinase inhibitor (EGFR TKI) that targets both EGFR-sensitizing and T790M resistance …
LBA1_PR: Osimertinib as first-line treatment for EGFR mutation-positive advanced NSCLC: updated efficacy and safety results from two Phase I expansion cohorts
S Ramalingam, JCH Yang, CK Lee, T Kurata… - Journal of Thoracic …, 2016 - jto.org
Background Osimertinib (AZD9291) is a potent, irreversible EGFR-TKI selective for EGFR-
TKI-sensitising (EGFRm) and T790M resistance mutations. We present updated efficacy and …
TKI-sensitising (EGFRm) and T790M resistance mutations. We present updated efficacy and …